
AbbVie Files BLA for TrenibotE in Glabellar Lines
AbbVie announced today it has submitted a Biologics License Application (BLA) to the US FDA for trenibotulinumtoxinE (TrenibotE), a first-in-class botulinum neurotoxin serotype E.1 If approved, this neurotoxin would serve as a fast-acting, short-term …